Luke Bromley

Luke Bromley

Auto-generated profile, based on publicly available information

Luke Bromley

Department of Surgery, Austin Health, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2020 in The Breast
Verified
Journal Article
Open access
PDF file
LBLuke Bromley
Luke Bromley
JXJennifer Xu
Jennifer Xu
SLSu-Wen Loh
Su-Wen Loh
GCGrace Chew
Grace Chew
ELEddie Lau
Eddie Lau
BYBelinda Yeo
Belinda Yeo
• Breast ultrasound in asymptomatic surveillance after breast cancer surgery was found to have a sensitivity of 44.1%. • Breast ultrasound detected 7 recurrences in 390 patients who did not meet criteria for adjunct breast US and had normal mammography • Breast ultrasound generated 26 additional biopsies per 1000 US compared to mammography in surveillance, creating considerablecosts. • Cancer detection by breast US alone did not lead to statistically significant survival benefit over mammography.

11 January 2023 in Anz Journal of Surgery
Verified
Journal Article
Closed access
LBLuke Bromley
Luke Bromley
DHDora Huang
Dora Huang
HMHelen Mohan
Helen Mohan
ARAmrish Rajkomar
Amrish Rajkomar
JLJosé Tomas Larach
José Tomas Larach
SWSatish Warrier
Satish Warrier

11 November 2025 in Cancer Control
Verified
Journal Article
Open access
LBLuke Bromley
Luke Bromley
CHChristopher Harris
Christopher Harris
LALuke Ardolino
Luke Ardolino
SWSanjay Warrier
Sanjay Warrier
AOAdam Ofri
Adam Ofri
Introduction: Chemotherapy is used frequently in the neoadjuvant setting for breast cancers, most commonly triple negative and human epidermal growth factor receptor 2 (HER-2) positive breast cancer. Certain hormone positive HER-2 negative cancers known as luminal B have shown response to adjuvant chemotherapy and can be considered in the neoadjuvant setting. This meta-analysis reviews survival outcomes in neoadjuvant chemotherapy in comparison to adjuvant in luminal B breast cancer. Methods: PubMed, Medline, and Embase were accessed on the 31 st of January 2024 to complete this systematic review and meta-analysis. All study types were included. Studies included compared survival rates in luminal B breast cancer patients in the neoadjuvant and adjuvant setting. All regimens of chemotherapy were included. Studies were included if they had at least median of 48 months follow up. Studies were excluded if they were non-comparative or did not report survival rates. Results: Two retrospective analyses comparing neoadjuvant and adjuvant chemotherapy were found from this systematic review, with a total of 4575 patients included. Of the 4575 patients, 679 received neoadjuvant chemotherapy (14.84%). Meta-analysis of these studies identified a non-significant trend of increased overall survival in the adjuvant chemotherapy arm with a hazard ratio of 1.85, confidence interval 0.98 – 3.48, ( P value 0.058). Discussion: This meta-analysis revealed a paucity of data in the comparison of neoadjuvant to adjuvant chemotherapy in luminal B breast cancer patients. Both studies identified were of a retrospective nature, and further research in this field should be considered.